TFR Capital LLC. Buys Shares of 7,966 Cencora, Inc. $COR

TFR Capital LLC. bought a new position in Cencora, Inc. (NYSE:COR) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 7,966 shares of the company’s stock, valued at approximately $2,254,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of COR. Kemnay Advisory Services Inc. purchased a new stake in shares of Cencora during the fourth quarter valued at $25,000. Oakworth Capital Inc. purchased a new stake in shares of Cencora during the 4th quarter valued at about $26,000. Elyxium Wealth LLC bought a new stake in shares of Cencora in the fourth quarter worth approximately $27,000. Elevation Wealth Partners LLC raised its holdings in shares of Cencora by 506.2% during the second quarter. Elevation Wealth Partners LLC now owns 97 shares of the company’s stock valued at $27,000 after purchasing an additional 81 shares during the last quarter. Finally, Archer Investment Corp lifted its position in Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after purchasing an additional 47 shares during the period. 97.52% of the stock is owned by institutional investors.

Cencora Stock Performance

Shares of COR opened at $313.86 on Friday. The business has a 50-day simple moving average of $298.98 and a two-hundred day simple moving average of $313.24. The company has a quick ratio of 0.58, a current ratio of 0.93 and a debt-to-equity ratio of 3.53. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The stock has a market cap of $59.89 billion, a price-to-earnings ratio of 23.32, a PEG ratio of 1.80 and a beta of 0.57.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.35 by $0.13. Cencora had a return on equity of 125.45% and a net margin of 0.79%.The company had revenue of $84.75 billion during the quarter, compared to the consensus estimate of $84.31 billion. During the same period in the previous year, the company posted $4.00 EPS. The firm’s revenue was up 5.1% on a year-over-year basis. On average, analysts expect that Cencora, Inc. will post 17.84 EPS for the current year.

Cencora announced that its Board of Directors has initiated a stock repurchase plan on Thursday, May 21st that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 3.9% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s management believes its shares are undervalued.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Friday, August 14th will be paid a dividend of $0.60 per share. The ex-dividend date is Friday, August 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. Cencora’s payout ratio is 17.83%.

Insiders Place Their Bets

In other news, Director Lauren M. Tyler bought 550 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was bought at an average price of $270.23 per share, with a total value of $148,626.50. Following the acquisition, the director owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. This represents a 14.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.38% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $382.00 to $390.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Wall Street Zen raised Cencora from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Robert W. Baird set a $370.00 price target on Cencora in a research note on Thursday, August 6th. Morgan Stanley increased their price objective on shares of Cencora from $342.00 to $346.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Barclays cut their target price on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Thirteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and a consensus target price of $374.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.